Search Results

By Geoffrey I. Shapiro, MD, PhD, Guest Editor  / May 10, 2017 - Supplement: CDK4/6 Inhibitors

Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting

The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...